Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ibcasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibcasertib overview
CS-2164 (Chiauranib) is under development for the treatment of small-cell lung cancer, fallopian tube cancer, relapsed and refractory non-Hodgkin lymphoma, epithelial ovarian cancer, liver cancer, ovarian cancer, colorectal cancer, kidney cancer, gastric cancer, lung cancer including non-small cell lung cancer, gastrointestinal stromal tumor, small-cell lung cancer, pancreatic ductal adenocarcinoma, non-small cell lung carcinoma, neuroendocrine tumors, hepatocellular carcinoma, breast cancer, peritoneal carcinoma, soft tissue sarcoma, triple-negative breast cancer (TNBC), HER2- Breast Cancer and other solid tumors and soft tissue sarcomas including liposarcoma, leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, fibrosarcoma sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, Ewing's sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberanoma, myofibroblastic sarcoma, malignant solitary fibroma, radiotherapy posterior sarcoma, acinar soft tissue sarcoma, well-differentiated/dedifferentiated liposarcoma, graft versus host disease, pancreatic cancer. It is administered through oral route in the form of capsule. It acts by targeting Aurora B, VEGFR, PDGFR, c-Kit and CSF1R. The drug candidate is being developed based on chemical genomics-based discovery platform.
It was also under development for the treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, small-cell lung cancer, renal cell carcinoma.
Shenzhen Chipscreen Biosciences overview
Shenzhen Chipscreen Biosciences (Chipscreen) is a biotechnology company. The company pipeline products include chidamide are for the treatment of peripheral T-cell lymphoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma (DLBCL), non-small cell lung cancer; chiglitazar treats type 2 diabetes, type 2 diabetes, non-alcoholic steatohepatitis, engliflozin-chiglitazar FDC (T2DM), metformin-chiglitazar FDC (T2DM); chiauranib for small cell lung cancer, small cell lung cancer/advanced solid tumor ib/lla, monotherapy, ovarian cancer, triple negative breast cancer, monotherapy and combination therapy, soft tissue sarcoma, pancreatic cancer, hematology; CS12192 treats rheumatoid arthritis (China), multiple sclerosis, inflammatory colitis, Ggraft-versus-host disease (GVHD), CS23546 targets Tumor; CS32582 for psoriasis. It operates in China. Chipscreen is headquartered in Shenzhen, Guangdong, China.
For a complete picture of Ibcasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
